
Amol Akhade/LinkedIn
Apr 22, 2025, 10:51
Amol Akhade: Sacituzumab govitecan plus pembrolizumab shows PFS benefit in metastatic TNBC
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospital, shared a post on LinkedIn:
“Today is day of press release.
Sacituzumab govitecan plus pembrolizumab shows PFS benefit over chemo plus Pembrolizumab in metastatic TNBC with CPS > 10.
Ascent 04 trial.
Looking forward to Magnitude of benifit.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 22, 2025, 12:05
Apr 22, 2025, 10:11
Apr 22, 2025, 10:03
Apr 22, 2025, 09:55